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Comparative ﬁtness analysis of D-cycloserine
resistant mutants reveals both ﬁtness-neutral and
high-ﬁtness cost genotypes
Dimitrios Evangelopoulos 1,6, Gareth A. Prosser1,5,6, Angela Rodgers1, Belinda M. Dagg2, Bhagwati Khatri2,
Mei Mei Ho2, Maximiliano G. Gutierrez 3, Teresa Cortes4 & Luiz Pedro S. de Carvalho 1
Drug resistant infections represent one of the most challenging medical problems of our time.
D-cycloserine is an antibiotic used for six decades without signiﬁcant appearance and dis-
semination of antibiotic resistant strains, making it an ideal model compound to understand
what drives resistance evasion. We therefore investigated why Mycobacterium tuberculosis
fails to become resistant to D-cycloserine. To address this question, we employed a combi-
nation of bacterial genetics, genomics, biochemistry and ﬁtness analysis in vitro, in macro-
phages and in mice. Altogether, our results suggest that the ultra-low rate of emergence of
D-cycloserine resistance mutations is the dominant biological factor delaying the appearance
of clinical resistance to this antibiotic. Furthermore, we also identiﬁed potential compensatory
mechanisms able to minimize the severe ﬁtness costs of primary D-cycloserine resistance
conferring mutations.
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The number of human infections caused by bacteria resis-tant to antibiotics has dramatically increased in the lastdecades1–3. Currently, almost all drug classes in clinical use
are matched by evolved mechanisms of resistance in bacteria4,5.
Some of these bacteria are pan-resistant and cannot be treated
with any approved drugs6. While we understand very well how
these antibiotics work and how antibiotic resistance works in
many cases, we still fail to recognize how some drugs select for
resistance in months while others need several decades, which is
deﬁned here as resistance evasion7,8.
As for all other human pathogens, Mycobacterium tuberculosis,
the etiological agent of human tuberculosis (TB), has acquired
mutations in its genome and evolved resistance mechanisms to
almost all drugs that it has encountered during chemotherapy9.
Currently, the genetic basis for ﬁrst-line and second-line anti-
biotic resistance in M. tuberculosis is well characterized, with a
few exceptions, one of them being the antibiotic D-cycloserine
(DCS)10. DCS belongs to the core second-line treatment group B
listed in the WHO guidelines for treatment of multidrug and
extensively drug-resistant-TB (MDR/XDR-TB)11. The mechan-
ism of DCS action has been well studied since its discovery in the
1950s. In all bacteria tested, DCS inhibits two enzymes of the D-
Ala-D-Ala branch of peptidoglycan biosynthesis: alanine race-
mase (Alr) and D-Ala:D-Ala ligase (Ddl)12,13. In M. tuberculosis,
it has been established that despite DCS still inhibiting both
targets, the principal mechanism of bacterial death is inhibition of
Ddl (encoded by the ddlA gene), instead of inhibition of Alr
(encoded by the alr gene)14,15. This conclusion is supported by
earlier independent work which demonstrates a high catalytic
excess of alanine racemase in Mycobacterium smegmatis16.
Surprisingly, until very recently there were no well-deﬁned,
associated mutations conferring DCS resistance in the clinic. As
DCS inhibits two essential targets, it is expected that it will display
a low frequency of high-level resistant isolates emerging in the
clinic17. In addition, there is no well-deﬁned critical concentra-
tion (CC) for DCS making the assignment of resistant isolates
problematic and often depending on different epidemiological
cutoffs18. Still, it has been described that in the fast-grower, free-
living M. smegmatis, artiﬁcial overexpression of both Alr and Ddl
result in DCS resistance19,20. Furthermore, a point mutation in
the cycA gene, encoding the DCS transporter, is responsible for
the natural DCS resistance of Mycobacterium bovis BCG21.
Recently, whole-genome sequencing (WGS) data from clinical
isolates including MDR and XDR-TB strains identiﬁed non-
synonymous single-nucleotide polymorphisms (SNP) in the alr
gene with the possibility of some of them conferring low-level
DCS resistance22–24. However, whether these SNPs are relevant
DCS-resistance mutations in M. tuberculosis remains unclear.
Given its activity and lack of reported resistance in strains
infecting humans, DCS has been called “the cornerstone option”
for treating drug-resistant TB cases25. In August 2018, WHO
released a recent report to highlight changes made for the treat-
ment of MDR-TB. It is now recommended by WHO that DCS
along with clofazimine will be added to all regimens for treating
MDR-TB patients11. Even though DCS is only been used to treat
multidrug-resistant TB infections (which account for almost half
a million cases per year), this feature makes DCS the only anti-
biotic that has been used in humans for almost seven decades that
has evaded resistance selection in bacterial populations26,27. From
a practical standpoint, the molecular and cellular determinants
for DCS resistance–evasion are highly attractive features that if
understood could be incorporated into antibiotic drug discovery
programs aimed at developing superior antimicrobial agents for
the treatment of TB and other infectious diseases.
In this study, we conﬁrm the ultra-low rate of emergence of
spontaneous mutations conferring DCS resistance in M.
tuberculosis. These mutants display signiﬁcant ﬁtness cost during
infection, but not in vitro. We also identiﬁed compensatory
mechanisms that are in place to cope with the initial ﬁtness cost
of the DCS-resistant (DCSR) mutants. Finally, we also char-
acterized the molecular and cellular basis of DCS resistance, with
Alr overexpression or Alr mutation being sufﬁcient to resist to
DCS treatment. Altogether, these results suggest that the lack of
clinical resistance to DCS is likely to be due to the ultra-low rate
of emergence of DCS-resistance mutations, as no-ﬁtness pheno-
types can appear and be propagated during infection.
Results
Low abundance of SNPs in DCS-related genes. To identify
possible clues of DCS resistance inM. tuberculosis, we ﬁrst analyzed
the distribution and frequency of SNPs in the DCS target genes alr,
ddlA, cycA as well as the ald gene, which has been recently sug-
gested to cause low-level DCS resistance24. We screened a published
data set comprising 1601 genomes of M. tuberculosis clinical iso-
lates28 and compared it to the polymorphisms found in rpoB and
gyrA, associated with drug resistance to rifampicin29 and ﬂuor-
oquinolones30, respectively. We identiﬁed scarce non-synonymous
SNPs in the ddlA (0.80%) and alr genes (0.98%), and a slightly
higher frequency of non-synonymous SNPs in the cycA (1.26%) and
ald genes (1.52 %) when compared with the gyrA and rpoB (1.99
and 1.85%, respectively) (Supplementary Fig. 1 and Supplementary
Data 1). The presence of rpoB mutations could be associated with
rifampicin mono-resistance or could be indicative of pre-MDR
strains. It is also worth mentioning that in this setting pre-existing
ﬂuoroquinolone mono-resistance could also be present31. There-
fore, these results demonstrate a low degree of SNPs in the genes
encoding DCS targets, in agreement with lack of DCS resistance in
clinical isolates. Together these data demonstrate that while we have
limited information on the potential genes involved in DCS resis-
tance, there is no experimentally validated phenotypic, cellular, and
molecular data supporting their role in DCS resistance, and thus
we decided to generate and study lab-derived spontaneous
DCS-resistant mutants.
DCS has an extremely low mutation rate. To investigate the
cause of such low-resistance incidence in M. tuberculosis, we ﬁrst
examined the rate of spontaneous mutations conferring resistance
to DCS, by carrying out ﬂuctuation analysis experiments, initially
employed by S. Luria and M. Delbrück32. Fluctuation analysis is a
parallel evolution experiment that allows the distinction between
spontaneous versus induced mutations and allows the determi-
nation of the mutation rates. Using this approach, we calculated
an ultra-low rate of emergence of spontaneous mutations con-
ferring DCS resistance in M. tuberculosis (in the order of 10−11
mutations per bacterium per cell division, Table 1), and that DCS
does not induce mutagenesis. This result is in agreement with the
only other report of the mutation rates of DCS with M. tuber-
culosis33. This ultra-low rate of emergence of DCS-resistance
mutations is consistent with DCS engaging two lethal targets in
Table 1 Mutation rates of DCS, RIF, and INH as calculated
from ﬂuctuation assays
Strain Drug Concentration
(μg/mL)
Mutation rate (μ) per
bacterium per cell
division
H37Rv DCS 100 1.63–1.79 × 10−11
H37Rv DCS 64 1.25–3.22 × 10−10
H37Rv RIF 2 3.21 × 10−9
H37Rv INH 1 4.86 × 10−8
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M. tuberculosis, Alr and Ddl, and represents an important barrier
for the selection of resistance. Another valid interpretation of this
ultra-low rate of DCS resistance is independent of the number of
targets engaged per se, and encompasses a ﬁnite number of
polymorphisms that can confer DCS resistance. In contrast, the
mutation rates for isoniazid and rifampicin, the two most com-
monly used anti-tubercular drugs were calculated at 4.8 × 10−8
and 3.2 × 10−9 mutations per bacterium per cell division,
respectively (Table 1). Nevertheless, under antibiotic pressure the
mutation rate for DCS might be different, as suggested from a
recent study reporting DCS clinical resistance22,24.
Alr is the sole contributor to DCS resistance in M. tuberculosis.
To investigate the likelihood of secondary compensatory muta-
tions and experimentally deﬁne the mechanisms responsible for
DCS resistance in M. tuberculosis, we isolated and characterized
11 spontaneous DCSR, obtained independently. All eleven
mutants are eightfold more resistant to DCS when compared with
the parent strain (Fig. 1a). In line with these results, all 11
mutants were also fourfold more resistant to terizidone (TRZ), a
better tolerated DCS pro-drug that contains two equivalents of
DCS per molecule34. In order to identify the genomic mutations
conferring DCS resistance, we whole-genome sequenced all 11
DCSR strains along with the parental M. tuberculosis H37Rv
strain (Supplementary Data 2). A total of 85 nonredundant SNPs
were identiﬁed across the resistant isolates, when compared
against the reference genome of M. tuberculosis H37Rv. After
excluding SNPs within repetitive regions, a total of 11 SNPs were
targeted for further analysis (Fig. 1b; Supplementary Data 3).
Among the genes known to be potential DCS targets or associated
with DCS resistance, we only detected mutations in the alr gene
(Fig. 1b, c). Eight out of the 11 mutants shared a non-
synonymous SNPs in position 3840391 (C > T), creating an
aspartate (D) to asparagine (N) substitution at codon 322 of
the Alr protein. Furthermore, DCSR8 and DCSR11 shared a
mutation located within the promoter region (C 3841405A) of the
alr gene. This mutation changes the −10 promoter region from a
non-TANNNT −10 motif to an extended −10 promoter con-
sensus sequence35, suggesting possible transcriptional changes. In
addition, we detected a 142 bp deletion upstream of the alr pro-
moter in DCSR5, possibly in a region where a transcriptional
regulator might bind. In silico analysis of transcriptional factor-
binding site indicates that no known transcriptional regulators
bind to this region, suggesting it could be a novel regulator. After
screening of these two SNPs in the Coll et al.28 dataset, only a
single occurrence of the ﬁrst SNP (C 3840391T; D322N) was
reported in a Russian strain belonging to lineage 1. Based on the
pattern of non-synonymous SNPs detected among the mutant
strains, we arranged them into six different groups (Fig. 1b, c).
Furthermore, mutations in the promoter or putative repressor site
of alr seem to have evolved in parallel, as all the secondary
mutations found in these strains are also present in the alr D322N
mutant strains. These data highlight the central role of alr in DCS
resistance in M. tuberculosis in vitro, which is in strict agreement
with the few identiﬁed and phenotypic validated clinical DCS-
resistant strains.
DCSR mutants do not exhibit cross-resistance. We next tested
the extent of resistance and whether these mutants display any
cross-resistance against other antitubercular drugs. Minimal
inhibitory concentrations (MIC90) were evaluated for all ﬁrst-line
and second-line antitubercular drugs, as well as other pepti-
doglycan targeting drugs. Interestingly, these mutants showed
differential susceptibility patterns when tested against vancomy-
cin (VAN) and teicoplanin (TEC). VAN and TEC are
glycopeptide antibiotics that bind to the terminal D-Ala:D-Ala
moiety of the pentapeptide stem of peptidoglycan and prevent the
cross-link of the peptidoglycan chains. Mutants DCSR1, DCSR2,
DCSR3, DCSR8, and DCSR11 were fourfold more resistant to
VAN, whereas the rest of the DCSR mutants were fourfold more
susceptible when comparing with parent strain (Fig. 1a). It seems
that the DCSR strains containing the mas gene (V1442G) SNP are
more resistant to VAN and TEC than the other strains. The mas
gene encodes a polyketide synthase involved in mycocerosic acid
synthesis, a part of the highly lipophilic outer membrane lipid
phthiocerol dimycocerosate (PDIM). In line with our results,
changes in PDIMs have been previously shown to affect the
susceptibility of M. tuberculosis strains to VAN36. Importantly,
not all DCSR mutants have altered PDIMs (Supplementary
Fig. 2). The sensitivity to glycopeptides, triggered by resistance to
DCS also highlights the collateral implications that certain anti-
biotic resistant strains may have with other antibiotics37. Of
broad interest, the fact that a single SNP can confer VAN resis-
tance in M. tuberculosis is highly unusual. For example, in
glycopeptide-resistant enterococci, mobile elements containing at
least four but up to seven genes are required to cause VAN
resistance38,39. Furthermore, we also performed MIC assays using
the automated BD BACTEC™ MGIT instrument as it is currently
used for drug susceptibility testing and determination of resis-
tance in clinical strains. In this assay the MIC value of the parent
H37Rv strain was 8 µg mL−1, whereas the MIC value for the
DCSR mutants was 64 µg mL−1. As there is no acceptable critical
concentration of DCS, using the most recently deﬁned epide-
miological cutoff of 64 µg mL−1 will classify these mutants as
DCS resistant18. Importantly, no cross-resistance to any ﬁrst-line
and second-line drugs was observed in the 11 DCSR mutants
(Fig. 1a), indicating that these strains bear mutations that are
speciﬁcally linked to DCS resistance.
DCSR mutants are ﬁt in vitro. We next sought to investigate the
potential ﬁtness cost that these mutations might confer, which if
high, could explain the scarcity of DCS-resistant M. tuberculosis
strains in the population. Given the slow-growing nature of M.
tuberculosis, we carried out these experiments as a function of
time, by measuring ﬁtness kinetics, instead of estimating ﬁtness at
a single arbitrarily chosen time. We examined ﬁtness in vitro, in
standard Middlebrook 7H9 medium, using a direct competition
assay; inside interferon-gamma-stimulated or naive human
monocyte-derived macrophages, and ﬁnally, in vivo in a mouse
model of infection (Fig. 2). In vitro, DCSR4, the mutant that
solely contains the primary mutation D322N in Alr exhibited a
very weak, transient ﬁtness cost (at days 7 and 14), which was not
statistically signiﬁcant. This difference was lost by the end of the
assay (day 56) (Fig. 2a). Similar ﬁtness kinetics were also observed
with DCSR5, the mutant having a deletion upstream of the alr
gene. Furthermore, the occurrence of the mas V1442G in DCSR1,
DCSR2, DCSR3, as well as the occurrence of ppsA E419K in the
DCSR7, DCSR9, and DCSR10 do not seem to bear any possible
ﬁtness cost in addition to the alr D322N SNP (Fig. 2a). Moreover,
mutants DCSR8 and DCSR11 containing the promoter SNP did
not exhibit any noticeable ﬁtness cost over time. The fact that
there were no DCS-resistant isolates obtained with only muta-
tions in the promoter region of alr indicates that the original
mutation might lead to a high-ﬁtness cost phenotype, and thus
either mutations in mas or rv2962c had to be established to
provide compensatory effects and survival of these strains prior to
promoter changes. DCSR7, DCSR9, and DCSR10 have an addi-
tional mutation at the ppsA gene (Rv2931) E419K encoding for a
polyketide synthase involved in the synthesis of phenolphthio-
cerol, also a part of PDIM molecules. The presence of these
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mutations in three different genes involved in PDIM biosynthesis
indicates that PDIM levels must have a protective effect, when
alr activity is affected. Likely, these modiﬁcations are making
M. tuberculosis further impermeable to DCS. Consistent with
these ﬁndings, it has been found that mutations in the ppsA gene
offer a ﬁtness beneﬁt in XDR strains40. In addition, different
mutations in the ppsA, ppsB, and ppsC genes have been implicated
in pyrazinoic acid resistance in M. bovis BCG41. Although the
mutations found by Gopal et al., and the ones described herein
are not the same, none of our 11 DCSR mutants showed any
changes in the MIC90 to pyrazinamide or pyrazinoic acid (Fig. 1c;
Supplementary Fig. 3). Interestingly, our ﬁtness kinetics experi-
ments reveal that there was no signiﬁcant ﬁtness cost associated
with mutations causing DCS resistance in vitro.
Some DCSR mutants are less ﬁt in human macrophages. We
then examined the uptake by and survival of the DCSR strains in
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resistant mutants (MIC90 fold change DCSR/parent strain). Drug abbreviations used: DCS D-cycloserine, TRZ terizidone, VAN vancomycin, TEC
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human monocyte-derived macrophages. All DCSR strains tested
were taken up similarly by macrophages (Fig. 2b). DCSR4,
bearing solely the D322N Alr mutation, was attenuated during
infection of naive and of interferon-gamma-activated human
macrophages, compared with the parent strain (Fig. 2b). The
presence of the mas V1442G or the ppsA E419K SNPs led to
compensatory beneﬁts as strains DCSR1, DCSR2, DCSR3, DCSR7,
DCSR8, DCSR9, DCSR10, and DCSR11 managed to infect, sur-
vive, and proliferate inside macrophages at similar levels com-
pared with the parent strain (Fig. 2b). In contrast, DCSR5, bearing
the deletion upstream of the alr gene and a SNP on rv2962c gene
encoding a rhamnosyltransferase involved in PDIM biosynth-
esis42, was signiﬁcantly attenuated for growth in human macro-
phages, compared with the parent strain (Fig. 2b). Similarly,
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DCSR6 was also attenuated in human macrophages, indicating an
associated ﬁtness cost with Rv2962c T234I and Alr D322N
mutations. These data suggest that some of the SNPs found in
DCSR strains affect the ability of M. tuberculosis to grow inside
human macrophages.
Some DCSR mutants are attenuated during mouse infection.
We next chose one DCSR strain representative of each group for
analysis of ﬁtness/attenuation in a mouse model of infection. In
agreement with the results obtained in human macrophages,
DCSR4 was signiﬁcantly attenuated in the mouse model, compared
with the parent strain, with a decrease in lung CFUs of more than
two log10 during the chronic phase of infection (Fig. 2c). This
failure to establish a high-burden infection in mice indicates that
the Alr D322N mutation impairs M. tuberculosis cellular viability.
The presence of the mas mutation (DCSR1) led to compensatory
effects during the mouse infection as we observed before in mac-
rophages. Unexpectedly, the presence of the ppsAmutation did not
compensate in vivo, as seen with the mutant DCSR9 (Fig. 2c). No
ﬁtness compensation was observed with DCSR strains having a
mutation at the putative rhamnosyltransferase (Uniprot ID
P9WN09), Rv2962c, including the alr repression mutant that was
also found to be attenuated in mice (Fig. 2c). These results indicate
that most of the DCSR strains incur signiﬁcant ﬁtness cost in vivo
that can be missed if only competition assays in vitro are used
without the presence of stresses found in the host (Fig. 2d). In this
case, clear compensatory mechanisms involving mas mutations
but not the ones in pssA and rv2962c can reverse the observed
ﬁtness costs associated with DCS resistance in vivo.
Overexpression of Alr causes DCS resistance. In order to
understand the molecular and cellular mechanisms involved in
DCS resistance in TB, we ﬁrst investigated the gene expression
pattern of a selected panel of genes including alr and ddlA,
encoding both targets of DCS. The DCSR5, DCSR8, and DCSR11
mutants that contained either mutations in the alr promoter or a
deletion upstream of alr overexpressed alr gene by more than 30-
fold when compared with the parent strain (Fig. 3a). This result
indicates that the large deletion upstream alr found in DCSR5
likely removes a transcription factor binding site for an as yet
unknown transcriptional repressor, but alternative mechanisms
that lead to enhanced gene expression could also be involved. In
contrast, all other DCSR strains displayed similar levels of alr
expression (Fig. 3a). There was no change in the expression of the
ddlA gene in any strains indicating again that ddlA is not linked
with DCS resistance in M. tuberculosis. Also, no changes in the
RNA levels of genes related to downstream biochemical reactions
in peptidoglycan biosynthesis such as murD, murF, and murI
were observed in any of the DCSR strains (Fig. 3a). In addition,
during an acute DCS treatment (high dose, short time), tran-
scriptional changes of these selected genes were partially altered
in the majority of the mutants. There is upregulation of DCS
targets, alr and ddlA, as well as cycA and the downstream pep-
tidoglycan biosynthesis-related genes murD, murF, and murI
(Fig. 3a). These subtler transcriptional changes likely indicate a
concerted effort to maintain the structural integrity of pepti-
doglycan in M. tuberculosis under DCS stress (Fig. 3a). We fur-
ther examined Alr protein levels, using a speciﬁc anti-Alr serum,
and found that Alr is also elevated in the DCSR5, DCSR8, and
DCSR11 strains (Fig. 3b), consistent with the increase in alr RNA
levels observed in Fig. 3a. Alr overexpression in DCSR5, DCSR8,
and DCSR11 was also observed during acute exposure to DCS.
Increased levels of Alr may serve the cell in two ways during DCS
exposure: (i) providing extra D-Ala which will protect Ddl from
DCS inhibition and (ii) removing free DCS from the cell, func-
tioning as a “sponge”, a mechanism already shown in ami-
noglycoside resistance43. Taken together, these results indicate
that overexpression of Alr alone is sufﬁcient to cause DCS
resistance in M. tuberculosis.
DCS inhibition is signiﬁcantly reduced on the Alr D322’N. We
next investigated the effect of the D322N substitution on Alr
activity, as this mutation was present in eight out of the 11
mutants isolated (~70% of the mutants). Analysis of the structure
of M. tuberculosis Alr indicates that D322 from the adjacent
monomer makes a water-mediated hydrogen bond with the
pyridoxal 5′-phosphate cofactor (Fig. 3c). As such we will refer to
it hereafter as D322’. Such an interaction suggests roles for this
residue in either ligand binding, catalysis, and/or inhibition.
Recombinant Alr (wild-type) and Alr D322’N were expressed,
puriﬁed and enzymatic activity as well as inhibition by DCS were
evaluated (Methods and Fig. 3d–g). We ﬁrst analyzed the pH
proﬁle of Ala racemization carried out by wild-type and the
D322’N mutant. Under kcat conditions, the D322’N mutant has
signiﬁcantly lower catalytic activity compared with wild-type Alr
across all pH values tested (Fig.3e). At neutral pH, Alr D322’N is
~20-fold slower than wild-type enzyme. Under kcat/Km condi-
tions, no differences were observed for wild-type and D322’N Alr
enzymes in the pH range tested. As DCS forms a covalent inhi-
bitor with alanine racemases pyridoxal 5′-phosphate cofactor and
IC50 measurements are misleading for irreversible inhibitors, we
evaluated kinact and Ki parameters for wild-type and D322’N
enzymes with DCS. The D322’N point mutation in Alr leads to a
240-fold decrease in the kinact/Ki for DCS (Fig. 3g). This result
indicates that despite the moderate impact under kcat conditions,
Alr D322’N is highly resistant to DCS inhibition. Separation of
kinact (rate of inactivation) and Ki (binding constant) parameters
revealed that the D322’N mutation leads to a loss of afﬁnity for
Fig. 2 Fitness cost kinetics of DCSR mutants. a Relative ﬁtness of DCSR mutants calculated using competition assays in vitro. DCSR mutants are grouped
according to their mutations and the relative ﬁtness is followed over time. Parent strain relative ﬁtness W= 1. The data are representative of three
independent experiments. The data points are representative of the mean, whereas error bars represent standard error SEM, n= 2. b Relative ﬁtness of
DCSR mutants obtained during macrophage infection. DCSR mutants are grouped according to their mutations. Experiments were carried out with human
blood-derived monocytes differentiated into macrophages. Bacterial uptake and survival inside naive or interferon-gamma-activated macrophages is
compared over time with the wild-type strain (black dots and line). The data shown are from one experiment representative of three independent
experiments, where each macrophage culture originated from at least three blood donors and were pooled prior to infection to minimize donor variability.
The data points are representative of the mean whereas error bars represent standard error SEM, n= 3. c Assessment of ﬁtness cost associated with DCS
resistance in the mouse model of infection. DCSR mutants (1, 4, 5, 6, 9, and 11) and parent strain were used in a low-dose aerosol infection murine model
(using C57BL/6 mice). The CFUs obtained from mouse lungs are shown for days 0, 30, 70 and 120 post infection. The data for DCSR4 are representative
of two independent experiments, whereas for DCSR mutants (1, 5, 6, 9, and 11) are from a single infection experiment. Five mice were infected per strain per
timepoint. The data points are representative of the mean, whereas error bars represent standard error SEM, n= 5. d The relative ﬁtness calculated for
representative DCSR mutants (1, 4, 5, 6, 9, and 11) at the endpoint in vitro (day 56) competition assays, macrophages infection assays (day 3), and in vivo
experiments (day 120), compared with the parent strain. Source data are provided as a Source Data ﬁle
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DCS (Fig. 3f), with only a very modest increase in the inactivation
rate (Fig. 3f). Together, these results indicate that the most
common mechanism to generate DCS resistance is by the mod-
iﬁcation of Alr, decreasing its afﬁnity for DCS. Decreased afﬁnity
for DCS would lead to more alanine racemisation, which in turn
would protect Ddl from inhibition, as DCS is a competitive
inhibitor against D-alanine.
Discussion
Prediction of resistance to novel antibiotics and pre-engineering/
selection of compounds with ultra-low rates of emergence of
resistance is essential for modern antibiotic development44. Two
more fundamental characteristics when evaluating drug resistance
are the inherent rate to which mutations conferring resistance can
arise in a particular pathogen, and the potential ways in which
ﬁtness cost can be mitigated by alternative or compensatory
mechanisms. The rate of spontaneous mutations conferring
resistance to DCS (mutation rate) is ultra-low in M. tuberculosis
(ca. 10−11) (ref. 33 and this work). Mutation rate is important, but
identifying and understanding potential routes for compensating
ﬁtness costs associated with resistance are equally important to
evaluate and predict resistance appearance and dynamics in
populations44. Estimation of ﬁtness costs not only in bacterial
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Fig. 3 Cellular and molecular determinants of DCS resistance inM. tuberculosis. a qPCR results for differential gene expression (log2 transformed) of selected
genes in the DCSR mutants grown in the absence or presence of DCS (10 ×MIC for 4 h). The results are representative of three biological replicates, n= 3.
b Western blot analysis of Alr expression in the DCSR mutants and parent strain grown in the presence or absence of DCS (10 ×MIC for 4 h). HisG levels
were used as loading control. The data are representative of two independent experiments. c Illustration of the active site of Alr from M. tuberculosis, 1XFC
[https://www.rcsb.org/structure/1XFC] highlighting the location of residue D322 and its interactions with the pyridoxal 5’-phosphate cofactor through a
water molecule-hydrogen bond network. d Reaction catalyzed by Alr and its inhibition by DCS. e pH-rate proﬁle of the reaction catalyzed by wild-type and
D322’N Alr. f, g Inactivation kinetics of wild-type (WT) and D322’N Alr by DCS at pH 7.5. Source data are provided as a Source Data ﬁle
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growth medium but also in cellular and whole-organism models
is essential to uncover the true likelihood of a genotype to be
propagated or eliminated from a population. We found that
generation of mutants in vitro is an ideal way to access high
variability of genotypes, which can then be studied in various
models. This contrasts with the use of clinical strains, which have
already been selected to allow growth in the host and therefore
will only have low to negligible ﬁtness costs45. In addition, we
found poor correlation between ﬁtness measured in growth
medium with ﬁtness measured in macrophages and mice. In vitro
estimations of bacterial ﬁtness, which are more commonly carried
out in a laboratory setting, seem to signiﬁcantly underestimate
phenotypes that are clearly observed in cellular or whole-
organism models. Moreover, we validated that the macrophage
model of infection might be a more reliable surrogate to evaluate
ﬁtness costs in vitro compared with conventional competition
assays in microbiological media (Fig. 2d).
This study is in agreement with studies highlighting the
implication of alr in DCS resistance in M. tuberculosis22,23. We
showed that there are two alr-related mechanisms underlying
DCS resistance: overexpression of Alr or reduction of the inhi-
bition of Alr through a previously unknown single-point muta-
tion. We showed that a promoter mutation upregulates alr gene
transcription and increases Alr protein level up to 30-fold (Fig.
3a, b). Consistent with this mechanism, mutations in the alr
promoter region have been found in clinical strains (position
3,841,356; G > A)22,46 in close proximity with our promoter
mutation found in DCSR8 and DCSR11 strains (3,841,405; C > A)
indicating a possible area for mutagenesis upstream of alr gene. In
addition to this mutation, we also observed a deletion further
upstream of the alr starting codon, possibly in an area where a
yet-to-be-identiﬁed transcriptional repressor might bind. This
deletion resulted in increased transcription of the alr gene with
concomitant Alr overexpression, as observed in the promoter
mutation strains. This mutation has not yet been found in the
clinic. In agreement with our results, Alr overexpression was
shown to be sufﬁcient to cause DCS resistance in M. tuberculosis,
where overexpression of Alr caused a sevenfold increase in the
MIC of DCS47. The most common DCS resistance mechanism
involves Alr modiﬁcation (D322’N). This mutation reduces the
afﬁnity of Alr by DCS by over 240-fold, with some associated
disruption of its catalytic activity. One XDR-TB strain contained
a mutation on the preceding residue, M221T, implicating the
importance of these two residues in the inhibition of Alr by DCS.
Furthermore, the fact that all DCS-resistant mechanisms pre-
sented here, also identiﬁed in clinical strains, involve mutations in
the alr locus and not in the ddlA locus highlights the importance
of Alr in generating DCS resistance. As both Alr and Ddl are part
of sequential enzymatic reactions and mutations in the ﬁrst gene,
alr, will lead to a less inhibited Alr enzyme and thus increased
levels of D-alanine will then out-compete DCS for the binding to
the Ddl. This result is in agreement with our previous ﬁndings
implicating Ddl and dipeptide synthesis as the lethal target of
DCS in M. tuberculosis. Mutation to ddlA gene could confer DCS
resistance, but it will not protect Alr from being inhibited by
DCS. Therefore, we believe that synthesis of the dipeptide is the
key for antibiotic mediated killing, while mutations on the alr
gene protect both targets.
In summary, DCS resistance is an ultra-rare event in M.
tuberculosis and secondary compensatory mutations, such as the
ones observed in the PDIM biosynthetic pathway, might alleviate
potential ﬁtness costs. Therefore, the lack of widespread clinical
resistance to DCS is due to the low mutational rate of M.
tuberculosis. DCS is known to inhibit two enzymes from the same
pathway, and therefore it seems reasonable to propose that
ﬁnding other molecules that truly inhibit more than one essential
enzyme is the most rational route to resistance-evading
antibiotics.
Lastly, the results of this work, in combination with clinical
WGS studies and phenotypic data can help improve the diagnosis
of DCS resistance through generation of molecular tools for
mapping DCS-conferring mutations. Importantly, our ﬁndings
can be utilized to improve the design of second-generation DCS
analogues that will maintain low mutation frequency and avoid
resistance while minimizing undesirable cytotoxic effects.
Methods
Materials. Unless otherwise stated, all the chemicals and reagents used in this
study were purchased from Sigma-Aldrich.
Bacterial strains and conditions. Mycobacterium tuberculosis laboratory strain
H37Rv was routinely cultured in Middlebrook 7H9 broth (Difco) supplemented
with either 10% (v/v) of ADC enrichment (Difco), 0.05% (v/v) tyloxapol, and
0.02% (v/v) glycerol or with 10% of (v/v) ADGNT solution (0.5% bovine serum
albumin, 2% dextrose 2% glycerol, 0.85% NaCl, and 0.4% tyloxapol) (c7H9). Liquid
cultures were grown at 37 °C either in 50 mL centrifugation tubes with rotation of
40 rpm or in roller bottles with a rotation of 2 rpm. For solid growth experiments,
M. tuberculosis H37Rv was grown in Middlebrook 7H10 (Difco) or Middlebrook
7H11 (Difco) agar medium supplemented with 10% (v/v) of OADC enrichment
(Difco) and 0.5% (v/v) glycerol (c7H10 or c7H11).
Calculation of DCS mutation rates. Mutation rates were calculated using the
ﬂuctuation assay and the Poison distribution methodology with few modiﬁca-
tions48. Brieﬂy, M. tuberculosis, starter cultures were inoculated from freezer stocks
until the culture reached an OD600 of 1 and ~300,000 cells were used to inoculate
120 mL of c7H9, giving a total cell count of 10,000 cells per 4 mL culture. This
volume was immediately divided to start 30 cultures of 4 mL each in 15 mL cen-
trifugation tubes. Cultures were grown at 37 °C with rotation of 40 rpm until
saturation (around 4 weeks). Following this, 26 cultures were spun at 3220 × g for
10 min at 4 °C. Cultures were then resuspended in 250–500 μL of 7H9 media and
spotted onto multiwell plates containing c7H10 agar medium supplemented with
the drug under investigation (DCS at 64 and 100 µg mL−1, RIF at 2 µg mL−1, and
INH at 1 µg mL−1). Once spread plates were allowed to dry and were subsequently
incubated at 37 °C for 1 month. Cell counts were determined by serial dilution of
four remaining random cultures. Following that, the mutation rates can be cal-
culated using the following formulas:
For the proportion (P0) of the cultures with no mutants
P0 ¼
no: of cultures with no mutants=growth
total no: of cultures i:e:; 26ð Þ ð1Þ
For the number of mutation per culture (m)
m ¼  ln P0ð Þ ð2Þ
Finally for the mutation rate (μ)
μ ¼ m
total CFUs
ð3Þ
Isolation of spontaneous D-cycloserine-resistant mutants. A fresh culture of
M. tuberculosis H37Rv was set up in 5 ml c7H9 and incubated shaking at 37 °C
until mid-exponential phase. The optical density was recorded and the culture
diluted to a ﬁnal OD600 of 0.000005 (~500 cells mL−1) in a total volume of 200 mL
c7H9. Aliquots were taken and spread on 7H11 plates for CFU analysis of initial
culture concentration. In total, 4 mL aliquots were then transferred into 60 indi-
vidual 15 mL sterile polystyrene culture tubes, and incubated with rotation at 37 °C
until saturation (~1 month). Aliquots were taken from select tubes and plated for
CFU analysis of ﬁnal culture concentrations. Tube contents were then inoculated,
in full, onto individual 47 mm 0.22 -µm nitrocellulose membrane ﬁlters by vacuum,
and the resulting bacteria-laden ﬁlters were transferred to individual c7H10 plates
containing DCS at 100 µg mL−1 (5 ×MIC). Plates were incubated at 37 °C, with
ﬁlters transferred to fresh plates every 8–9 days for a period of 5 to 7 weeks.
Individual colonies were then picked and inoculated into fresh c7H9, and freezer
stocks generated. In addition, potential mutants were also spreaded on c7H10
plates containing 100 µg mL−1 of DCS to verify heritable acquisition of
DCS resistance.
Minimum inhibition concentration assays. Cultures were inoculated to a ﬁnal
OD600 of 0.001 into 100 µL of 7H9 in 96-well microtiter plates, with twofold serial
dilutions of test compound going down each row (ﬁnal column left without any
drug). Top concentrations were chosen on a per-drug basis. Plates were incubated
at 37 °C for 6 days, and then a solution containing 0.02% of resazurin dye was
added on all the wells and incubated for another day. Minimum inhibition
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concentrations (MIC90) was calculated using visual determination of the lowest
concentration of drug at which there was no change in the resazurin color.
Determination of MICs were also performed using the automated BD
BACTEC™ MGIT™ 960 Instrument. Positive MGIT tubes containing the DCSR and
parent wild-type strains were used to inoculate new tubes containing DCS at ﬁnal
concentrations of 0, 2, 4, 8, 16, 32, 64, and 128, µg mL−1, in duplicates. In the
MGIT, the lowest concentration of DCS that prevented the generation of
ﬂorescence from the DCS-containing tube within 2 days of the no drug control
tube was deﬁned as the MIC.
Whole-genome sequencing. In all, 2 mL of stationary phase cultures of desired
strains were harvested by centrifugation, resuspended in 0.2 mL TE buffer, and
heat-killed at 80 °C for 1 h. Genomic DNA was extracted using the Zymo gDNA
extraction and genomic DNA clean and concentrator kits, following the manu-
facturer’s protocols. Quality and quantity of genomic DNA were conﬁrmed by
agarose gel electrophoresis, and DNA sequencing performed on an Illumina HiSeq
2000 instrument at the Cricks Genomic Science Technology Platform.
Mapping genome data and SNP calling. Sequencing reads for the WT and the 11
DCSR mutant strains were mapped against the M. tuberculosis H37Rv reference
genome (AL123456) as single-end data using the Burrows-Wheeler algorithm
described in BWA49 (Supplementary Data 1). Mapping outputs were used to
generate SNP calls using SAMtools49. Filtering of SNP calls was performed by
keeping those SNPs with minimum mapping quality of 10 and maximum read
depth of 400. These high conﬁdence calls were used to generate a nonredundant list
of variable positions called in at least one strain and used to recover the base call in
all other strains. Finally, SNPs positions that involved heterozygous calls or felt in a
repetitive or mobile element were removed. Functional annotation of each of the
polymorphic positions identiﬁed was performed using ANNOVAR50. The SNPs
identiﬁed are listed in Supplementary Data 2. All genome data is available in
ArrayExpress under accession number E-MTAB-5935.
Sanger sequencing. DNA fragments including the identiﬁed SNPs were ampliﬁed
via PCR with speciﬁc primers outlined in Supplementary Data 4, PCR amplicons
were then puriﬁed using a Qiagen PCR clean up kit and then sent for Sanger
sequencing at GATC Ltd (Germany). Sequencing ﬁles were visualized and com-
pared to wild-type using the Unipro UGENE software.
Competition assays. M. tuberculosis H37Rv parent strain and all DCS-resistant
mutants were grown at 37 °C in c7H9 media until late logarithmic phase separately
in roller bottles. The cultures were then diluted and a new set of cultures initiated
by co-culturing together the parent strain and each of the DCS-resistant mutant at
an equal ratio (2 × 105 CFUs) and incubated over the course of the competition
assay for 56 days. An aliquot of the mixed culture was taken at the following
timepoints, 0, 7, 14, 28, and 56 days, serially diluted and plated in triplicate in
c7H10 plates with and without 30 µg mL−1 of DCS for CFU determination. CFUs
were counted following 1 month of incubation at 37 °C. Three independent
experiments were performed with duplicate cultures in each of them. The relative
ﬁtness of the DCS susceptible over the DCS-resistant strains was calculated using
the formula:
W ¼ lnðRe
Rb
Þ  lnðSe
Sb
Þ ð4Þ
Where Re and Se are the number of resistant and susceptible bacilli at the endpoint
(7, 14, 28, and 56 days), respectively, and Rb and Sb are the number of resistant and
susceptible bacilli at the baseline, time 0.
Infection of human monocyte-derived macrophages. White blood cells were
isolated from leukocyte cones (NC24) supplied by the NHS Blood and Transplant
service, UK and complied with the UK Human Tissue Act regulations. GM-CSF-
derived macrophages were plated in 24-well tissue culture plates at a ﬁnal con-
centration of 2 × 105 cells per well 1 day prior to infection. M. tuberculosis cultures
were grown to the mid-log phase (OD600 ~0.8). Prior to infection, M. tuberculosis
cultures were harvested by centrifugation at 3000 rpm for 5 min and washed once
with PBS and once with cell culture media (RPMI with 10% FCS). An equal volume
of sterile glass beads (2.5–3.5 mm) that matched the pellet size was added and
vigorously shaken for 1 min to make single-cell suspension. The bacteria were then
resuspended in cell culture media and spun at 1200 rpm for 5 min. Following
centrifugation, the supernatant containing single-bacterial cells was transferred into
a new tube, OD600 was measured and the culture was diluted accordingly to 0.1 OD
to make the infection solution (~8 × 108 cells mL−1). Macrophages were then
washed and suspended with 0.25 mL per well of the infection solution (MOI of 1)
for 2 h. Following infection, macrophages were then washed three times with PBS
and suspended with cell culture media for the course of infection.
CFU determination. For counting bacterial viability, macrophages were washed
once with PBS to remove extracellular bacteria and lysed with 0.5 mL of
water–Tween-80 (0.05%) per well for 1 h at room temperature. The lysed solution
from the triplicate wells was then used for serial tenfold dilutions in PBS–Tween-80
(0.05%). In all, 20 µL from each dilution was then plated in triplicate onto c7H11
agar plates. Agar plates were incubated for 3–4 weeks at 37 °C. CFU counts were
calculated and plotted as the mean CFU per mL.
Mouse infections. C57BL/6J (WT) mice were bred and maintained under speciﬁc
pathogen-free conditions at The Francis Crick Institute, Mill Hill Lab or purchased
from Charles River. All studies were ethically reviewed and approved by the
respective ethical review committees at the Francis Crick Institute and NIBSC.
Procedures involving mice were performed in strict accordance with the United
Kingdom Animals (Scientiﬁc Procedures) Act 1986 and the respective Institutes
policies on the Care, Welfare and Treatment of Animals. Procedures were done
under UK Home Ofﬁce animal licenses 70/8045 and P7611793C. Animals were
monitored by trained animal technicians at least once a day, and this frequency
could increase if any adverse reactions were observed. Infections were performed in
the containment level 3 animal facilities either at the Mill Hill Lab or NIBSC. For
mouse infections, M. tuberculosis H37Rv and DCS-resistant strains were cultured
in c7H9 broth, to an OD600 of 0.6. From this, an infection sample was prepared to
enable delivery of about 100 CFUs/mouse lung using a nebulizer system (Walkers,
UK) linked to a Middlebrook airborne infection device (Glas-col, Terre Haute,
USA). Infection was monitored by assessing homogenized lungs from infected mice
at deﬁned time intervals. Bacterial counts were determined by plating serial dilu-
tions of homogenates on duplicate c7H11. CFUs were counted 2–3 weeks after
incubation at 37 °C. The data at each timepoint are the means of ﬁve mice per
group ± standard error (SEM).
RNA extraction and quantitative qPCR. Early logarithmic phase cultures of M.
tuberculosis and DCS-resistant mutants were grown in triplicates and then either
treated with 10 ×MIC of DCS or carrier control for 4 h. Following treatment,
cultures were spun down at 3000 × g for 5 min at 4 °C, supernatant discarded and
suspended in 1 mL of Trizol reagent and transferred into a 2 -mL tube containing
lysing matrix B beads (MP Biomedicals). Samples were lysed using a ribolyser at
6.5 speed for 45 s twice. Following ribolysis, samples were spun down, and the RNA
was puriﬁed using the Direct-zolTM−96 RNA kit (Zymo Research) following the
manufacturer’s instructions with the on column DNase treatment. Following RNA
puriﬁcation, the RNA was further DNase treated by a vigorous treatment using the
Ambion DNA Free kit according to the manufacturer’s instructions. RNA quantity
and quality was estimated using NanoDrop and 1.5 µg of RNA was used to make
cDNA according the High-Capacity RNA-to-DNA kit (Applied Biosystems).
qPCRs were done using TaqMan probe assays to quantify the levels of a selection of
genes (Supplementary Data 4) on a QuantStudio 5 Real-Time PCR System. PCR
efﬁciencies and limit of detection were calculated for each TaqMAn assay using
genomic DNA from M. tuberculosis. Differential gene expression was calculated
using the cloud-based AB software.
Western blotting. Early logarithmic phase cultures of M. tuberculosis and DCS-
resistant mutants were grown in and either treated with 10 ×MIC of DCS or carrier
control for 4 h. Following treatment, the cultures were spun down at 3000 × g for 5
min at 4 °C, supernatant was discarded, and the pellet was washed twice with PBS
solution and suspended into 1 mL of protein lysis buffer (20 mM TAE pH 7.8, 8 M
urea, 10% glycerol and 5 mM TCEP (Tris[2-carboxyethyl]phosphine hydro-
chloride)) and transferred into a 2- mL tube containing lysing matrix B beads (MP
Biomedicals). Bacterial suspensions were lysed using a ribolyser at 6.5 speed, 45 s,
three times with intermittent cooling on ice, followed by centrifugation at top speed
for 10 min in a refrigerated microcentrifuge. The supernatants containing soluble
protein fractions were then passed through a 0.22 µm pore-size spin ﬁlter, and
stored at −80 °C until further use. Thirty micrograms of protein of each sample
were run per lane of a SDS-PAGE gel alongside Odyssey® One-Color Protein
Molecular Weight Markers (Li-Cor Bioscience) and blotted to polyvinylidine
ﬂuoride membranes using iBlot 2 Dry Blotting System (ThermoFisher Scientiﬁc).
Membranes were blocked using the Odyssey Blocking buffer (Li-Cor Bioscience)
for 2 h at room temperature and subsequently probed with primary rabbit-raised
anti-MtAlr antibody (1:5000 dilution) overnight at 4 °C. Following washing,
membranes were incubated for 1 h with IRDye 800CW Goat anti-Rabbit IgG (Li-
Cor Bioscience) secondary antibody, and the immunoblots were developed using
the Odyssey CLx Imaging System (Li-Cor Bioscience).
Recombinant Alr puriﬁcation. MtAlr D322N was generated using QuickChange
mutagenesis (Agilent; cloning primers; Supplementary Data 4), and pET28:MtAlr
as a template. Recombinant proteins (including Escherichia coli L-alanine dehy-
drogenase; EcLADH) were expressed in E. coli BL21(DE3) and puriﬁed by nickel-
afﬁnity chromatography51. Both enzymes were co-expressed with the myco-
bacterial and E. coli GroEL and GroES chaperone proteins, respectively. Puriﬁed
histidine-tags were removed using thrombin (Restriction grade, GE Healthcare)
and dialyzed three times to remove the cleaved tags in 20 mM TEA or 20 mM
NaPO4, 150 mM NaCl, pH 7.8, concentrated, ﬂash frozen, and stored at −80 °C
until activity assays.
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MtAlr activity measurements. Alanine racemase activity was measured in the L-
Ala to D-Ala direction51. Brieﬂy, reactions containing 50 mM buffer (see below), 5
mM α-ketogluratate, 0.25 mM NADH, 18–28 U ml-1 LDH (used as a mixture of
pyruvate kinase/lactate dehydrogenase for convenience; Sigma), 4 μM BsDAAT,
and varying concentrations of L-Ala were combined with 10–100 nM recombinant
enzyme and monitored at 340 nm. Buffers used for each pH were HEPES (7.62,
7.12), Tris (7.92), TAPS (8.18), MOPS (6.86), CHES (8.9), PIPES (6.57), and MES
(6.3). All reactions were performed at 37 °C. Km and kcat values were calculated by
ﬁtting data to the Michaelis–Menten equation.
DCS inactivation reactions comprised 5 µM recombinant Alr, 20 mM sodium
phosphate buffer (pH 7.5 or 6.85), 150 mM NaCl, and varying concentrations of
DCS. Reactions were commenced upon addition of DCS. At distinct timepoints
during the incubation (including a time 0, before DCS was added), aliquots were
removed and added to activity reactions, comprising 50 mM CHES pH 8.9, 5 mM
NAD+, 20 mM D-Ala, and 30 µL mL−1 EcLADH. Activity reaction progression
was monitored at 340 nm.
Activity at time t was re-calculated as a percentage of the initial activity of the
enzyme (activity at t0). Plots of ln(% activity) vs. time were linear in all cases. The
slope of each plot allowed calculation of the kobs for each inhibitor concentration
tested, per Eqs. (1) and (2):
VðtÞ=Vð0Þ ¼ a ´ e kobs ´ tð Þ ð5Þ
ln VðtÞ=Vð0Þð Þ ¼ kobs ´ t þ a ð6Þ
Where a is a Y-axis normalization factor, V(t) is activity at time t, and V(0) is
activity at time 0. Nonlinear regression analysis of replots of kobs vs. inhibitor
concentration allowed calculation of kinact and Ki, per Eq. (3):
kobs ¼ kinact ´ I½ ð Þ= Ki þ I½ ð Þ ð7Þ
Lipid extraction. Early logarithmic phase cultures of M. tuberculosis and DCS-
resistant mutants were grown for lipid proﬁling. Apolar lipids were extracted
following established procedures as previously described52. Brieﬂy, 20 mL of M.
tuberculosis H37Rv and DCS-resistant strains were cultured in c7H9 broth, to an
OD600 of 2, harvested via centrifugation at 3000 × g for 5 min and transferred to 1
mL of PBS solution in a 2 mL screw cap tubes and heat inactivated at 90 °C for 2 h.
Lipids were extracted from the remaining biomass in a mixture of methanol:
chloroform (2:1) overnight, followed by a second extraction of methanol: chloro-
form (1:1) for 5 h at room temperature. Pooled lipid mixture was then dried at
50 °C under a nitrogen stream. Extracted lipids were dissolved in chloroform and
subsequently analyzed using thin layer chromatography. The extracted lipids were
then analyzed using two-dimensional TLC with system A solvents consisting of
petroleum ether–ethyl acetate (98:2), three times in the ﬁrst direction and petro-
leum ether–acetone (98:2), once in the second direction. TLC plates were visualized
using a 5% phosphomolybdic acid solution in ethanol followed by gentle charring
of the plates with a heat-gun.
Statistical analysis. GraphPad Prism 7 was used for all statistical analysis. Three
independent experiments per assay were performed and statistical analysis was
carried out by unpaired t test of the biological replicates of each experiment.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
Whole-genome sequencing data of the strains used in this study are available in
ArrayExpress (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5935. The
data underlying Figs. 1, 2, and 3 are provided in the Source Data ﬁle. All other data are
available from the corresponding author upon reasonable requests.
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